Shares of Globus Medical, Inc. (NYSE:GMED – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve brokerages that are presently covering the stock, MarketBeat reports.

CBN has fined nine banks N1.35 billion for failing to ensure Naira notes availability through ATMs during the festive season.

Photo provided to chinadaily.com.cn] China's flooring industry is expecting robust growth and to provide the international ...

The Kremlin earned some €3 billion in 2023 in tax from European Union companies that were, and sometimes still are, active in ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical (NYSE:GMED – Free Report) had its target price increased by Canaccord Genuity Group from $92.00 to $101.00 in ...

BTIG analyst Ryan Zimmerman reiterated a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $91.00. The ...

Globus Medical Inc (GMED) stock saw a modest uptick, ending the day at $87.07 which represents a slight increase of $0.52 or 0.60% from the prior close of $86.55. The stock opened at $88.5 and touched ...

Biotech stock GeneDx broke out after the FDA issued its first AI rules for medical devices. Globus Medical and GeneDx are in ...

Two oil and gas stocks hit 52-week highs as energy prices popped Friday. The stocks are in buy zones while a medical device ...

Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

在其他近期新闻中，Globus Medical因其强劲的第四季度收入和积极的2025年展望而受到各方分析师的关注。公司报告第四季度销售额为6.57亿美元，超过了市场预期。2024年全年销售额也大幅增长，达到约25.2亿美元。